# NSN 6505-01-642-0106: Adenovirus Type 4 And Type 7 Vac

NSN 6505-01-642-0106 (also written 6505016420106; NIIN 01-642-0106) is an adenovirus type 4 and type 7 vac in Federal Supply Class 6505, Drugs and Biologicals. 4 manufacturer part numbers from 4 suppliers are on record. It was last purchased in Sep 2026.

## Identification

- NSN: 6505-01-642-0106 (6505016420106)
- NIIN: 01-642-0106 (016420106)
- Item name: ADENOVIRUS TYPE 4 AND TYPE 7 VAC
- Federal Supply Class: [FSC 6505 Drugs and Biologicals](https://nsnexplorer.com/fsc/6505/)
- Federal Supply Group: [FSG 65](https://nsnexplorer.com/group/65/)
- Acquisition method suffix code: AMSC Z: a commercial, nondevelopmental or off-the-shelf item. (observed 2026-10-20)
- Acquisition method code: 3

## Characteristics

| Code | Requirement | Reply |
| --- | --- | --- |
| CXCY | PART NAME ASSIGNED BY CONTROLLING AGENCY | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIVE ORAL ENTERIC COATED TABLETS 200S |
| FEAT | SPECIAL FEATURES | CONTAINS VIABLE, SELECTED STRAINS OF HUMAN ADENOVIRUS TYPE 4 AND HUMAN ADENOVIRUS TYPE 7 PREPARED IN HUMAN-DIPLOID FIBROBLAST CELL CULTURES (STRAIN WI-38); VIRUS STRAINS HAVE NOT BEEN ATTENUATED; CELLS ARE GROWN AND THE VIRUS GROWTH MAINTAINED IN DULBECCO'S MODIFIED EAGLE'S MEDIUM, FETAL BOVINE SERUM, AND SODIUM BICARBONATE; APPROVED FOR USE IN MILITARY POPULATIONS 17-50 YEARS OF AGE; INDICATED FOR ACTIVE IMMUNIZATION FOR THE PREVENTION OF FEBRILE ACUTE RESPIRATORY DISEASE CAUSED BY ADENOVIRUS TYPE 4 AND TYPE 7; CARTON CONSISTS OF ONE BOTTLE OF 100 TABLETS ADENOVIRUS TYPE 4 (NDC 51285-174-02) AND ONE BOTTLE OF 100 TABLETS ADENOVIRUS TYPE 7 (NDC 51285-175-02); STORE REFRIGERATED BETWEEN 2-8 DEG C (35-46 DEG F); DO NOT FREEZE; KEEP BOTTLE TIGHTLY CLOSED AND PROTECT FROM MOISTURE; DO NOT REMOVE DESICCANT CANISTER FROM BOTTLE; PRESCRIPTION ONLY; FOR ORAL ADMINISTRATION; DOSAGE: ONE TABLET OF ADENOVIRUS TYPE 4 COMPONENT AND ONE TABLET OF ADENOVIRUS TYPE 7 COMPONENT |

## Part numbers

| Part number | CAGE | Supplier | Source |
| --- | --- | --- | --- |
| 1281637 | 89875 | DEFENSE LOGISTICS AGENCY DIRECTORATE OF MEDICAL MATERIEL DEFENSE SUPPLY CENTER PHILADELPHIA | [flis](https://www.dla.mil/Portals/104/Documents/InformationOperations/LogisticsInformationServices/FOIA/PUBLOG/) |
| 6505NCM151649 | 64616 | DEFENSE MEDICAL STANDARDIZATION BOARD | [flis](https://www.dla.mil/Portals/104/Documents/InformationOperations/LogisticsInformationServices/FOIA/PUBLOG/) |
| NDC51285-0138-50 | 3V8D7 | TEVA PHARMACEUTICALS USA, INC. | [flis](https://www.dla.mil/Portals/104/Documents/InformationOperations/LogisticsInformationServices/FOIA/PUBLOG/) |
| NDC51285-0138-50 | 56490 | BARR LABORATORIES, INC. DBA BARR LABORATORIES, INC INC | [flis](https://www.dla.mil/Portals/104/Documents/InformationOperations/LogisticsInformationServices/FOIA/PUBLOG/) |

## Contract awards

Newest first.

| Date | Award | Description | Recipient | Amount |
| --- | --- | --- | --- | --- |
| 2026-09-16 | [SPE2DP20D0002/SPE2DP26F9980](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $171,763.20 |
| 2026-09-16 | [SPE2DP20D0002/SPE2DP26F9977](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $343,526.40 |
| 2026-09-16 | [SPE2DP20D0002/SPE2DP26F9976](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $343,526.40 |
| 2026-09-16 | [SPE2DP20D0002/SPE2DP26F9975](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $515,289.60 |
| 2026-09-16 | [SPE2DP20D0002/SPE2DP26F9974](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $687,052.80 |
| 2026-09-16 | [SPE2DP20D0002/SPE2DP26F9973](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $343,526.40 |
| 2026-09-16 | [SPE2DP20D0002/SPE2DP26F9971](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $515,289.60 |
| 2026-08-12 | [SPE2DP20D0002/SPE2DP26F8916](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $171,763.20 |
| 2026-08-12 | [SPE2DP20D0002/SPE2DP26F8915](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $343,526.40 |
| 2026-08-12 | [SPE2DP20D0002/SPE2DP26F8914](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $515,289.60 |
| 2026-08-12 | [SPE2DP20D0002/SPE2DP26F8913](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $687,052.80 |
| 2026-08-12 | [SPE2DP20D0002/SPE2DP26F8912](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $343,526.40 |
| 2026-08-12 | [SPE2DP20D0002/SPE2DP26F8911](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $343,526.40 |
| 2026-08-12 | [SPE2DP20D0002/SPE2DP26F8910](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $1,030,579.20 |
| 2026-08-12 | [SPE2DP20D0002/SPE2DP26F8909](https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106) | ADENOVIRUS TYPE 4 AND TYPE 7 VACCINE LIV | TEVA PHARMACEUTICALS USA, INC. | $515,289.60 |

## Sources

- DLA DIBBS RFQs for this NSN: https://www.dibbs.bsm.dla.mil/RFQ/RFQNsn.aspx?value=6505016420106&category=nsn
- DLA DIBBS awards for this NSN: https://www.dibbs.bsm.dla.mil/Awards/AwdRecs.aspx?category=awdnsn&TypeSrch=cq&Value=6505016420106
- AMSC record: https://www.dla.mil/Portals/104/Documents/InformationOperations/LogisticsInformationServices/FOIA/PUBLOG/
- USAspending contract actions (each award above links to its record)
- All data is public U.S. government data; every row above links to its source record where one exists.

Canonical page: https://nsnexplorer.com/nsn/6505-01-642-0106/
JSON: https://nsnexplorer.com/api/nsn/6505-01-642-0106.json